Meitheal partners with Chinese company for US licencing of insulin biosimilars
The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.
News
Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine
CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar
Kezar and Everest enter lupus nephritis therapy development deal
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
Signal: Fresh Tracks nears end of operations with plans for dissolution
EC grants approval for Menarini’s breast cancer therapy
AbCellera and Regeneron expand antibody discovery collaboration
